Ambrosia Biosciences is aiming to move the market beyond peptide-based obesity treatments and initiate a trial for its oral ...

A team of researchers from NYU Abu Dhabi and the University of Denver have identified a promising small molecule that could ...

A diabetes drug called lixisenatide has produced the first strong clinical evidence that a small molecule can slow the actual ...

Platform screens up to 10 billion compounds in hours, delivering wet-lab-ready candidates in weeks without requiring 3D ...

Scientists at the Buck Institute for Research on Aging have shown that an orally administered small molecule, ...

Colorado drugmaker Ambrosia Biosciences has landed $100 million to pursue an oral obesity drug it’s hoping can compete with a ...

Food does not affect Foundayo, so it can be taken with or without food. In contrast, oral Wegovy has to be taken on an empty ...

Ambrosia Biosciences. The financing provides $100 million in committed capital, intended to fund the Company through clinical ...

In a new study, researchers have identified a way to stop cells from dying, opening the door to developing treatments that slow the progression of neurodegenerative conditions like Parkinson’s disease ...

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ...

Experts from the University of of Dundee's Centre for Targeted Protein Degradation (CeTPD), working with Boehringer Ingelheim scientists, have developed a breakthrough small-molecule drug, a "protein ...